ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

PHS Plans Revitalization of Commissioned Corps

July 11, 2003

NCI Offers Fellowship Training In Epidemiology & Genetics.

February 18, 2000

Safety Concerns About Saltz Regimen Were Statistical Artifact, ODAC Finds.

December 14, 2001

NCAB Working Group Renamed, Adds Karen Antman

December 16, 1994

Somatuline Demonstrates 65.1 Percent Of Patients Progression-Free at 96 Weeks

July 25, 2014

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003